Abstract

Despite the importance of radiation therapy as a nonsurgical treatment for non-small cell lung cancer (NSCLC), radiation resistance has always been a concern because of poor patient response and outcomes. Therefore, it is crucial to identify novel targets to increase the effectiveness of radiotherapy and investigate the mechanisms underlying radioresistance. Previously, we demonstrated that Spindlin 1 (SPIN1) was related to tumour initiation and progression. In this study, we found that SPIN1 expression was higher in NSCLC tissues and cell lines than in the corresponding controls. SPIN1 overexpression in NSCLC patients was closely correlated with disease progression and poor prognosis. Functionally, SPIN1 depletion inhibited cell proliferation, decreased the percentage of cells in the G2/M phase and suppressed cell migration and invasion. Moreover, SPIN1 knockdown decreased the clonogenic capacity, impaired double-strand break (DSB) repair and increased NSCLC radiosensitivity. Mechanistically, forkhead box M1 (FOXM1) was identified as a key downstream effector of SPIN1 in NSCLC cells. Furthermore, SPIN1 was found to facilitate MDM2-mediated FOXO3a ubiquitination and degradation, leading to FOXM1 upregulation. Moreover, restoration of FOXM1 expression markedly abolished the inhibitory effects and increased radiosensitivity induced by SPIN1 depletion. These results indicate that the SPIN1-MDM2-FOXO3a/FOXM1 signalling axis is essential for NSCLC progression and radioresistance and could serve as a therapeutic target for increasing radiotherapy efficacy.

Details

Title
SPIN1 accelerates tumorigenesis and confers radioresistance in non-small cell lung cancer by orchestrating the FOXO3a/FOXM1 axis
Author
Zhong, Min 1 ; Fang, Zhi 2   VIAFID ORCID Logo  ; Zou, Juntao 3 ; Chen, Xiao 2   VIAFID ORCID Logo  ; Qiu, Zezhi 2   VIAFID ORCID Logo  ; Zhou, Ling 2 ; Le, Yi 2   VIAFID ORCID Logo  ; Chen, Zhen 4   VIAFID ORCID Logo  ; Liao, Yanyu 4   VIAFID ORCID Logo  ; Nie, Fengting 4   VIAFID ORCID Logo  ; Wei, Xianpin 4 ; Zhan, Jinbo 5   VIAFID ORCID Logo  ; Xiong, Jianping 4   VIAFID ORCID Logo  ; Xiang, Xiaojun 4   VIAFID ORCID Logo  ; Fang, Ziling 4 

 the First Affiliated Hospital of Nanchang University, Department of Oncology, Nanchang, PR China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073); Jiangxi Key Laboratory for Individualized Cancer Therapy, Nanchang, PR China (GRID:grid.412604.5); the First Affiliated Hospital of Nanchang University, Department of Respiratory, Nanchang, PR China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073) 
 the First Affiliated Hospital of Nanchang University, Department of Oncology, Nanchang, PR China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073); Jiangxi Key Laboratory for Individualized Cancer Therapy, Nanchang, PR China (GRID:grid.412604.5) 
 the First Affiliated Hospital of Nanchang University, Department of Respiratory, Nanchang, PR China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073) 
 the First Affiliated Hospital of Nanchang University, Department of Oncology, Nanchang, PR China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073) 
 Jiangxi Key Laboratory for Individualized Cancer Therapy, Nanchang, PR China (GRID:grid.412604.5) 
Pages
832
Publication year
2024
Publication date
Nov 2024
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3128897305
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.